Podcasts about morphosys

Der DAX verlor 1,4 % und schloss bei 19.970 Punkten, im Tagestief war es bei 19.959. Der EUROSTOXX50 büßte 1,6 % ein und landete bei 4877 Punkten. An der Wall Street eröffnete der Dow Jones mit +1 % bei 42.717 Punkten. Die gestrige Fed-Sitzung brachte eine Wende: Zinssenkungen bleiben Thema, aber datenbasierte Entscheidungen stehen künftig im Fokus. Für 2025 deutet sich eine Pause im Zinssenkungszyklus an. - Firmen im Fokus: Adnoc erwirbt 91,3 % der Covestro-Aktien und zwingt den Konzern zum DAX-Austritt. Novartis schließt Morphosys bis 2025, betroffen sind 330 Arbeitsplätze. Douglas erwartet für 2024/25 bis zu 4,8 Mrd. Euro Umsatz und plant deutliche Gewinnsteigerungen. Würth rechnet mit einem Gewinneinbruch von 25–30 % und leicht sinkendem Umsatz für 2024. Apple und Meta streiten über das europäische Digitalmarktgesetz. Die Bank of England belässt ihren Leitzins bei 4,75 %. Spruch des Tages von Wolfgang Juds: "In der Euphorie vergessen die Anleger ihre Vorsicht - und in der Krise vergessen sie ihren Mut."

This week on Careers in Discovery, I'm joined by Dr Peter Pack, an influential figure in the Biotech industry whose journey has taken him from Germany to the dynamic Biotech landscape of the UK, where he now operates as a strategic partner and advisor to Private Equity firms and startups. In our conversation, Peter shared his diverse experience, including his time as a CEO for nearly 20 years and his current role mentoring young biotech teams. He offered insights into the differences between the Biotech industries in Germany and the UK, the importance of building strong networks, and his passion for supporting innovative startups. Peter also reflected on his early inspirations in science, the development of groundbreaking technologies at Morphosys, and the valuable lessons he has learned about commercialization and strategic decision-making. He emphasized the importance of collaboration, learning from mistakes, and the critical role of supportive investors. Join us as we explore Peter's fascinating career, his views on the future of biotech, and the key factors that contribute to successful leadership in this ever-evolving field.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Moritz Seyffarth und Nando Sommerfeldt über die Metamorphose bei Morphosys, neuen Optimismus bei Ryanair und eine erstaunliche Nvidia-Kurs-Prognose. Außerdem geht es um Easyjet, Wizz Air, Lufthansa, Super Micro Computer, Curaleaf, Canopy Growth, Verano Holdings, Alphabet, Microsoft, Circus und Rational. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Allen fundamentalen Hiobsbotschaften zum Trotz geht es beim DAX in Richtung Rekordhoch. Heute stieg der DAX um 0,4 % auf 18.682 Punkte, nahe dem Tageshoch von 18.724 Punkten und damit nicht weit vom Rekordstand bei 18.893 Punkten entfernt. Zyklische Werte wie Minen-, Auto- und Chemieaktien waren gefragt. Die wirtschaftliche Lage bleibt angespannt: Das BIP sank im zweiten Quartal um 0,1 %, doch die Bundesbank erwartet für das laufende Quartal eine leichte Erholung. Firmenmeldungen: Thyssenkrupp unter Druck wegen der Zukunft der Stahlsparte. TUI sichert 75.000 zusätzliche Urlaubsplätze für den Herbst. Ryanair kürzt sein Berlin-Angebot um 20 %. Boeing sieht Chinas Flugzeugflotte auf Wachstumskurs. BHP steigert den bereinigten Gewinn um 2 % auf 13,6 Milliarden Dollar. Morphosys-Minderheitsaktionäre erhalten 68 Euro pro Aktie von Novartis. In den Interviews heute: Heiko Thieme, "Die Märkte bleiben spannend, aber Vorsicht ist geboten." Make Cliq Digital Fit for Future. FACC CFO Heindl auf dem HIT: "Die Wahrheit liegt in der Brieftasche!" Wenn der Postmann gar nicht klingelt. Binect-CEO Wermeyer. Grüne Schifffahrt und nachhaltige Infrastruktur: Die brandneue Strategie der MPC Capital AG und Rolf Piepers neuen Podcast: "Pieper ohne Filter."

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über AMDs Angriff auf Nvidia, Monster-Rallye für mpox-Aktien und eine Mega-Fusion im Späti-Markt. Außerdem geht es um Rheinmetall, Hensoldt, Renk, Bayer, Estée Lauder, AMD, Nvidia, Virax, Bavarian Nordic, GeoVax Labs, Seven & i Holding, Alimentation Couche-Tard, Palo Alto, Monster, Celsius, Crowdstrike, Varta, Porsche, Voltabox, Morphosys, Novartis, Singulus, Delivery Hero, Bike24 Holding, Douglas, Brain Biotech, Mister Spex, Vita34, TUI, AboutYou, RWE, E.On, Siltronic, Deutsche Telekom, Villeroy und Boch, Thyssenkrupp, Bilfinger, Siemens Healthineers, Rheinmetall, Schott Pharma, SAP, Nemetschek, Vanguard FTSE All World (WKN: A2PKXG), Xtrackers MSCI World ex USA (WKN: DBX0VH), Invesco EQQQ Nasdaq 100 ETF (WKN: 801498) und iShares Core S&P 500 ETF (WKN: A0YEDG). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

This week on Careers in Discovery, we are joined by Peter Pack, an influential figure in the biotechnology industry with a career spanning over two decades. Peter's journey has taken him from Germany to the dynamic biotech landscape of the UK, where he now operates as a strategic partner and advisor to private equity firms and startups. In our conversation, Peter shares his diverse experiences, including his time as a CEO for nearly 20 years and his current role mentoring young biotech teams. He offers insights into the differences between the biotech industries in Germany and the UK, the importance of building strong networks, and his passion for supporting innovative startups. Peter also reflects on his early inspirations in science, the development of groundbreaking technologies at Morphosys, and the valuable lessons he has learned about commercialization and strategic decision-making. He emphasizes the importance of collaboration, learning from mistakes, and the critical role of supportive investors. Join us as we explore Peter's fascinating career, his views on the future of biotech, and the key factors that contribute to successful leadership in this ever-evolving field. Don't miss this episode full of insights from a biotech veteran who continues to shape the industry.

TV-Duell der US-Präsidentschaftskandidaten

In der heutigen Folge von “Alles auf Aktien” sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über fettige Gewinne für JM Smucker, ehrgeizige Expansionspläne von Robinhood und enttäuschende Zahlen bei DocuSign. Außerdem geht es um Vonovia, LEG, Aroundtown, Deutsche Bank, Commerzbank, Nvidia, Gamestop, Robinhood, DocuSign, JM Smucker, Nemetschek, SAP, Tui, Rational, Deutsche Börse, Traton, Morphosys, Sixt, SMA Solar, Nvidia Amazon, Apple, Alphabet, Tesla, Chipotle, Zoologischer Garten Berlin, Gelsenwasser, Mainova, Lindt & Sprüngli, NVR, Booking Holdings, Autozone, O‘Reilly Automotive, Fair Isaac, Deckers Outdoor, Regeneron Pharmaceuticals, LPP, Hermes, LVMH, Adyen, ASML, Broadcom, Costco, Eli Lilly, Intuit, Netflix, ServiceNow, BlackRock, Rational, Münchener Rück und Rheinmetall. Eure Sprachnachrichten für die 1000. Folge schickt ihr bitte an die Nummer: 0170/3753558. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Und sie bewegt sich doch. Die EZB hat die Zinsen gesenkt. Von 4 % auf 3,75 %, also 25 Basispunkte. Ob das schon eine echte Zinswende ist, warten wir ab. In den kommenden Tagen wird es etliche Analysen hierzu geben. Auch bei uns im Programm. Der DAX war am Vormittag noch aufgeregt in Richtung 18.800 Punkte gelaufen. Mit der - erwarteten - Zinssenkung hat er dann die Tagesgewinne weitgehend abgegeben. Es bleibt ein kleines Plus von 80 Punkten. 18. 653 Punkte, plus 0,4 %. Die Immobilientitel geben auf breiter Front nach. Die US-Börsen ebenfalls nur moderat im Plus. Dort kommen morgen am Freitag die Zahlen vom Arbeitsmarkt. Gestern noch Spekulation, heute die Fakten: Die Indizes der DAX-Familie wurden neu bestückt. Keine Änderung im DAX, einige dagegen in der zweiten Reihe. Traton, TUI und Rational sind ab Ende Juni in MDAX und ersetzen Sixt, SMA und MorphoSys.

Der Markt legt nach dem Durchhänger vom Dienstag heute am Mittwoch wieder zu. Das Signal ist eindeutig. Man hofft auf die Zinswende. Morgen, am Donnerstag, seitens der EZB. Quasi letzter Anschub für Christine Lagarde könnten die Erzeugerpreise sein, die im Euroraum nochmal deutlich zurückgegangen sind. Zeitgleich verfestigt sich die gute Stimmung unter den Einkaufsmanagern, der Wert liegt jetzt bei 52,2 Punkten und ist damit nochmal besser als im April. Stühlerücken könnte es im MDAX geben, nach der turnusmäßigen Überprüfung. SMA und MorphoSys könnten gehen, TUI könnte kommen. Im SDAX könnte es für Douglas heißen: Come In. Find Out dagegen für Heideldruck. Alles noch Spekulation. Eine gute Nachricht gab es für Bayer. In einem der zahlreichen Glyphosat-Prozesse hat eine US-Richterin die Ansprüche der Kläger zusammengestrichen, von 2,2 Mrd. auf nur noch 400 Mio. Bayer 1 % Plus. Mehr Dividende könnte es zukünftig und dauerhaft bei SAP geben. 1,7 % plus die Aktie. Und noch die Schlusskurse Frankfurt: DAX +0,9 % bei 18.576 Punkten. MDAX +0,7 % bei 26.966 Punkten. Gewinner des Wiener Börsenpreises: https://go.brn-ag.de/339

Anleger werden mutiger angesichts sinkender Zinsen und schieben den DAX bis auf knapp 18.700 Punkte am Nachmittag. In der Schlussauktion haben sie dann wohl doch wieder Angst vor der eigenen Courage und der Markt gibt einen Teil der Gewinne wieder ab. Es bleibt ein Plus von 110 Punkten. Schlusskurse Frankfurt: DAX +0,6 % bei 18.608 Punkten. MDAX +0,9 % bei 26.963 Punkten. Rückenwind geben nicht nur die Zinshoffnungen, sondern auch eine freundliche Wall Street. Analysten sehen mit dem heutigen Tag die Zwischenkorrektur als beendet an. Auch Heiko Thieme sieht es ähnlich. In der exklusiven Klubausgabe sagt er sinngemäß, dass er im Sommer noch mit volatilen Korrekturen rechnet, die gute Einstiegschancen sind. So liegt der Fokus auf dem Donnerstag und der Zinsentscheidung der EZB. Angesichts motivierender Inflationsdaten rechnet der Markt mit einer Senkung von 25 Basispunkten. Am Mittwoch werden die Mitglieder der Indizes in Frankfurt überprüft. SMA und Morphosys werden vermutlich den MDAX verlassen. Verlierer des Tages sind die Papiere des BVB. Nach der Niederlage im Finale der Champions League geben die Aktien 6 % nach. Gewinner des Tages sind GameStop. Nach einer spekulativen Meldung auf Reddit hatte sich der Kurs in der Spitze mit 80 % fast verdoppelt. Am Nachmittag flaute der Hype wieder etwas ab. Es bleiben 30 % Aufschlag.

On this week's Biotech Hangout, hosts Daphne Zohar, Eric Schmidt, Yaron Werber and Luba Greenwood are joined by special guest and STAT reporter, Adam Feuerstein. The episode kicks off with the hosts sharing their thoughts on industry sentiment and some of the revealing trends in the week's Stifel report before diving into Q1 earning reports from Ascendis, Amgen and SpringWorks. The hosts talk about ONO's acquisition of Deciphera for $2.4B, X4's FDA approval of XOLREMDI, and how COVID fatigue could be causing us to minimize the threat of the avian influenza H5N1.  The group also discusses Biden's Cancer Moonshot getting killed by Congress, a federal judge throws out two drugmaker IRA lawsuits and the FTC goes after drug company's “junk” patents in obesity and other device combos. Adam sparks a group discussion around his exclusive STAT article on how an emerging safety issue in MorphoSys' Phase 3 cancer study may complicate its acquisition by Novartis. Other topics covered this week include BridgeBio spinning out an oncology company as it focuses on the anticipated launch of its heart drug, US government moving to reclassify marijuana from schedule 1 to schedule 111 drug, and more. *This episode aired on May 3, 2024.

On this week's Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Tim Opler, Chris Garabedian and Grace Colon discuss the latest in biotech news, including another strong week of IPOs, most notably with Kyverna Therapeutics' IPO upsizing by 49% to $300M. On the acquisition theme, the hosts discuss Novartis' plans to acquire MorphoSys for $2.9B and Gilead walking away from its acquisition of Tizona. The hosts also cover some obesity-related updates, including Lilly's tirzepatide Phase 2 trial for MASH and Amgen's Phase 1 data for weight-loss candidate, MariTide. Other data discussed this week includes Vertex's ‘vanza triple,' 4D Molecular Therapeutics' interim Phase 2 data in wet AMD and J&J's Phase 3 with Nipocalimab. Additional topics of discussion include plans by Novo Holdings (Novo Nordisk's parent company) to buy Catalent to boost Wegovy supply, the FDA modernizing the way it tracks post-market data by using AI, and Scion Life Sciences' debut with a new $310M fund. *This episode aired on February 9, 2024.

Fri, 16 Feb 2024 11:37:00 +0000 https://jungeanleger.podigee.io/1348-wiener-borse-party-590-small-caps-werden-heute-gespannt-auf-aluflexpacks-66-prozent-move-schauen-morphosys-lasst-grussen 16e7cab5d3951ab8c4cefcd3406f71df Die Wiener Börse Party (556 Folgen lang hiess es Wiener Börse Plausch) ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm.. Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse. Inhalte der Folge #590: - ATX deutlich im Plus - Februar-Verfallstag - Constantia Flexibles will Aluflexpack, die Aktie letzterer steigt 66 Prozent (Morphosys lässt grüssen) - News zu Porr, Do & Co - 5. Geburtstag der ÖBAG - Research zu Post und Porr - Weiter gehts im Podcast Links: Börsenradio Live-Blick 16/2: DAX-Rekordjagd + Verfallstag = Bären heute unter Druck, Treasury-Festspiele Siemens, guter Porr-Move. Hören: https://open.spotify.com/episode/7HKE2Q8upovqhfsDmzhsF8 - Playlist 30x30 Finanzwissen pur für Österreich auf Spotify: https://open.spotify.com/playlist/3MfSMoCXAJMdQGwjpjgmLm - Stockpicking Österreich: https://www.wikifolio.com/de/at/w/wfdrastil1? ATX aktuell: https://www.wienerborse.at/indizes/aktuelle-indexwerte/preise-mitglieder/??ISIN=AT0000999982&ID_NOTATION=92866&cHash=49b7ab71e783b5ef2864ad3c8a5cdbc1 Die 2024er-Folgen vom Wiener Börse Plausch (Co-verantwortlich Script: Christine Petzwinkler) sind präsentiert von Wienerberger, CEO Heimo Scheuch hat sich ebenfalls unter die Podcaster gemischt: https://open.spotify.com/show/5D4Gz8bpAYNAI6tg7H695E  . Co-Presenter im Februar ist Schwabe, Ley & Greiner https://www.slg.co.at . Der Theme-Song wurde seinerzeit spontan von der Rosinger Group supportet: Sound & Lyrics unter http://www.audio-cd.at/page/podcast/2734 . Mehr Wiener Börse Pläusche: https://www.audio-cd.at/wienerboerseplausch  . Risikohinweis: Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: https://podcasts.apple.com/at/podcast/audio-cd-at-indie-podcasts-wiener-boerse-sport-musik-und-mehr/id1484919130 . 1348 full no

Technologie regiert die Welt – ob Künstliche Intelligenz, Daten-Plattformen oder Chipfabriken. Was läge da näher, als in einen Tech-ETF anzusparen. Ein Sparplan mit einer monatlichen Rate von 100 Euro hätte über 39 Jahre eine Million mehr Vermögen eingebracht. Die beiden Wirtschaftsjournalisten Dietmar Deffner und Holger Zschäpitz diskutieren darüber, was für den Nasdaq-ETF und was für den altehrwürdigen MSCI World spricht. Weitere Themen: - Lichtblick bei Wind und Solar – warum der Deffner an eine Wende glaubt - Digitale Wüste Deutschland – warum Bayern im Ranking abgestiegen ist und wer jetzt vor und hinten liegt - Zweifelhaftes grünes Bekenntnis – warum Zschäpitz seinen AEG-Kühlschrank nicht wegschmeißen möchte und wie Ihr ihm helfen könnt - Übernahmepoker um Morphosys – warum es sinnvoll sein könnte, zu verkaufen - Hidden Champion – welche Aktie der Zschäpitz auf der Skipiste angetroffen hat Die wichtigsten News an den Märkten und das Finanzthema des Tages hören Sie morgens ab 5 Uhr bei „Alles auf Aktien“ – dem täglichen Börsen-Shot aus der WELT-Wirtschaftsredaktion. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutzerklärung: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. In our first news, Walgreens has appointed Mary Langowski as the new president of its U.S. healthcare segment, replacing John Driscoll. Molina Healthcare has reported a loss of 500,000 members due to redeterminations, but expects proposed 2025 rates to boost its benchmark rate. UnitedHealth's COO, Dirk McMahon, is retiring after two decades at the company. The American Hospital Association (AHA) has called for more payer oversight in resolving disputes over surprise medical bills.Moving on to the next news, Amgen, Roche, and Pfizer are looking to enter the GLP-1 weight loss market, challenging Novo Nordisk and Eli Lilly. These companies are developing their own versions of diabetes and weight loss drugs. Smaller biotech companies have also shown promising results in clinical trials with their own GLP-1 agonists. Amgen, Roche, and Pfizer are currently in the clinical stages of developing their GLP-1 receptor agonists and could soon enter the weight loss and obesity markets.In financial news, Eli Lilly has reported revenue of over $9.3 billion in Q4 2023, surpassing expectations. The company credits the strong performance to the demand for their weight-loss drug Zepbound and the diabetes treatment Mounjaro. Vertex Pharmaceuticals announced positive results for its cystic fibrosis triple combination therapy in two randomized controlled trials. GlaxoSmithKline's Blenrep combination therapy also achieved a phase III win in multiple myeloma. Novartis has acquired German biotech company MorphoSys to strengthen its oncology portfolio. Bristol Myers Squibb highlighted their comprehensive approach to cancer research.Shifting gears to regulatory news, the FDA panel has recommended new standards for pulse oximeters due to concerns of bias. Cardinal Health has expanded its recall of Monoject syringes due to compatibility problems. The FDA is planning to reclassify most high-risk in vitro diagnostic devices (IVDs) to ease the path for clearance. Edwards has received FDA approval for the first transcatheter tricuspid valve replacement treatment. ECRI has identified usability challenges for at-home devices and inadequate device cleaning instructions as top health technology hazards.Finally, several biopharmaceutical companies are focusing on neuroinflammation as a potential target for treating Alzheimer's disease. Vertex Pharmaceuticals' non-opioid pain drug, VX-548, recently failed in a Phase III trial. Bristol Myers Squibb takes a comprehensive approach to cancer research. Takeda's immunoglobulin therapy for Clostridium difficile infection (CDI) has been approved by the FDA. Novartis has dropped a blood cancer asset after disappointing Phase III results. Merck's Keytruda has achieved Phase III wins in kidney and bladder cancer. BMS's Opdivo has failed in a late-stage kidney cancer trial.These developments indicate positive progress in the pharmaceutical industry, particularly in the areas of cancer treatment and rare diseases like cystic fibrosis. Companies continue to innovate and strive for breakthrough therapies that can improve patient outcomes.Thank you for listening to Pharma and Biotech Daily. Stay tuned for more updates in the world of Pharma and Biotech.

In der neuesten Folge unseres Aktienpodcasts, präsentiert von Philipp und Marcel von Modern Value Investing, tauchen wir tief in die Welt der Künstlichen Intelligenz (KI) und analysieren die jüngsten Quartalszahlen führender Unternehmen. Erfahren Sie, wie Palantir als "Lionel Messi der KI" den Markt beeindruckt, warum Air Products & Chemicals trotz einer unter den Erwartungen liegenden Prognose eine Chance darstellen könnte, und wie Disney sich im Mediensektor mit einem innovativen Sport-Streaming-Deal positioniert. Wir diskutieren auch bedeutende Bewegungen im Pharmasektor, darunter die Übernahme von Catalent durch Novo Nordisk und Novartis' Kauf von MorphoSys, sowie den erfolgreichen Renk IPO, der neue Wachstumsmöglichkeiten im Verteidigungs- und Energiesektor eröffnet. Außerdem beleuchten wir die Herausforderungen und Chancen für Unternehmen wie BAT, die ihre Beteiligung in Indien verkaufen wollen, und Disney, das mit Vorschlägen für den Aufsichtsrat konfrontiert ist. Nicht zu vergessen die Expansion von Flixbus nach Indien, die Veröffentlichung der Apple Vision Pro, die Herausforderungen von WeWork und Alibaba sowie die Frage, wie weit der KI-Trend wirklich geht. Unsere Investmentideen der Woche, Flixmobility und Fortinet, bieten spannende Perspektiven für Anleger, die am Puls der Zeit bleiben wollen. Verpassen Sie nicht unsere tiefgehenden Analysen und Einsichten in die Dynamik des Aktienmarkts.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Philipp Vetter über Hoffnung aus China, Fusions-Fantasien in der Pharma-Branche und einen Staats-Verkauf bei DHL. Außerdem geht es um Morphosys, Qiagen, Bayer, Evotec, Infineon, Walt Disney, Fox, Warner Bros. Discovery, FMC Corp., Adobe, AMD, Mercadolibre, Synopsis, DocuSign, Renk, Volkswagen, Auto1, Porsche AG, Schott Pharma, Hensoldt, Mercedes-Benz, BMW, Stellantis, Inditex, Hermès, Beiersdorf, Xtrackers MSCI World Consumer Discretionary (WKN: A113FH), Vanguard USD Corp. 1-3 Year Bond Acc(WKN: A2PCCG) und Xtrackers S&P500 Equal Weight (WKN: A1106A). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

UBS posts a better-than-expected Q4 net loss of $279m. U.S. markets are in the red as the 2-years Treasury yield reaches a one-month high as strong services numbers pushes back expectations of an early Fed rate cut. In China, authorities move to mitigate a slump in the stock market helping both the Hong Kong and Shenzhen indices up. In pharma news, Novartis buys up cancer treatment firm MorphoSys while Novo Nordisk snaps up a key manufacturing sub-contractor for its obesity drug WeGovy. BoE chief economist Huw Pill says it is a matter of when, not if, the central bank moves to cut rates after retail sales slow in January. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Laurin Meyer über einen historischen Schritt von Beiersdorf, Rekordhoch bei Nvidia und einen hastigen Börsengang. Außerdem geht es um Morphosys, Novartis, Lufthansa, Thyssenkrupp, Goldman Sachs, Snap, Estée Lauder, Palantir, Airbus, Boeing, Novo Nordisk, Visa, Mastercard, Deutsche Bank, ING, BNP Paribas, Commerzbank, Adyen, Paypal, Hyundai Motor, Xtrackers MSCI World Health Care (WKN: A113FD), Invesco European Food & Beverages Sector ETF (WKN: A0RPR6) und DWS Concept Food (WKN: 848665). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Alle Infos zu ausgewählten Werbepartnern findest du hier.  Das Buch zum Podcast? JETZT BESTELLEN.  Lieber als Newsletter? Geht auch.  Cannabis, Morphosys und Novo Nordisk beflügeln die Börse. Außerdem finden Investoren gut, wenn Estée Lauder Mitarbeiter feuert und nicht gut, wenn Snap das tut. Achja: Unicredit zahlt Dividende, McDonald's leidet unter Boykotts, Boeing bohrt falsche Löcher. Für Anleger sind Fonds oft teuer. Für Anima (WKN: A110YL) sind sie umso lukrativer. Volvo will Polestar (WKN: A3DP4R) nicht mehr unterstützen. Zum Glück springt Geely ein. Sollte man jetzt mitspringen? Diesen Podcast vom 06.02.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

US equity futures are indicating a broadly flat open as of 05:00 ET. This follows mixed markets in Asia, while European equity markets are slightly higher. The bond market selloff is being attributed to the repricing of the Fed rate path. China equities are rebounding following new intervention headlines. Corporate earnings continue today, with reporting companies including Eli Lilly and Amgen.Companies Mentioned: Novartis, Morphosys

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über eine Zocker-Idee für die Berichtssaison, eine Shortattacke auf Morphosys und was sonst noch wichtig wird in dieser Woche. Außerdem geht es um BASF, Netflix, Tesla, Intel, IBM, D.R. Horton, Teledyne, Valero Energy, Apple, Google, Microsoft, Amazon, McDonald's, Visa, Tencent, Mastercard, Coca Cola, Telekom, SAP, Mercedes Benz, BMW, Siemens, Samsung, Toyota, Nike, Palantir, C3.AI, Accenture, Salesforce, Qualcomm, Fujitsu, Cognizant, Intel, Infosys, Wipro, Meta, Zurich, Workday und VanEck Morningstar DM Dividend Leaders (WKN: A2JAHJ). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Alle Infos zu ausgewählten Werbepartnern findest du hier.  Das Buch zum Podcast? JETZT BESTELLEN.  Lieber als Newsletter? Geht auch.  Allzeithoch beim DAX. Pelabresib-Hoch bei Morphosys. Absage-Hoch bei Cigna. Außerdem wird Macy's wohl gekauft und Occidental Petroleum hat wohl gekauft. Aumann (WKN: A2DAM0) sollte eigentlich was vom E-Auto-Hype abkriegen. Stattdessen hat die Firma viel von der Corona-Krise abgekriegt. Aber was passiert jetzt? Costco (WKN: 888351) ist sehr teuer. Doch die Rentabilität ist sehr hoch, Charlie Munger hat die Firma geliebt und Diebe haben Costco schon immer gehasst. Diesen Podcast vom 12.12.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Alle Infos zu ausgewählten Werbepartnern findest du hier.  Das Buch zum Podcast? JETZT BESTELLEN.  Lieber als Newsletter? Geht auch.  Der Sohn von Christine Lagarde hat Bitcoin-Verbot. ImmunoGen mag AbbVie. SAP erreicht Allzeithoch. Dr. Martens hat ein US-Problem und Morphosys ist grundlos glücklich. Es geht um den größten Juwelenraub der Geschichte. Keine Sorge, wir machen kein True-Crime, sondern sprechen über die Werttransporter von Brink's (WKN: 264748). Coinbase (WKN: A2QP7J) wird zu Stablebase. Diesen Podcast vom 01.12.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Nando Sommerfeldt über die unheilvolle Xmas-Trübsal, die verschobene Zinswette der Wall Street und flüchtiges Glück bei Morphosys. Außerdem geht es um Kohl's, Best Buy, Lowe's, American Eagle Outfitters, Abercrombie&Fitch, Microsoft, Teamviewer, Morphosys, Rheinmetall, Siemens Energy, Stellantis, Volkswagen, Amazon, Alphabet, Intel, AMD, DWS Laufzeiten ETF September 2027 (WKN: DBX0VA), Laufzeit September 2029 (WKN: DBX0VB), Laufzeit September 2031 (WKN: DBX0VC) und Laufzeit September 2033 (WKN: DBX0VD). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Alle Infos zu ausgewählten Werbepartnern findest du hier.  Das Buch zum Podcast? JETZT BESTELLEN.  Lieber als Newsletter? Geht auch.  Morphosys hat ein Studienproblem. TeamViewer hat ein Aktionärsproblem. Abercrombie & Fitch hat Quartalszahlen und ein rentables 2023. Außerdem gibt's Zahlen von NVIDIA. Mehr Rendite als alle anderen US-Banken. Eigentümer, die den Nachnamen Holding haben. Eine der genialsten Übernahmen ever. First Citizens BancShares (WKN: A3D2CQ) ist High-Performer. Snoop Dogg raucht nicht mehr. Solo Brands (WKN: A3C59Z) liebt alles daran. Diesen Podcast vom 22.11.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

In maydornsmeinung analysiert Börsenexperte Alfred Maydorn die neuesten Entwicklungen der beliebtesten Aktien deutscher Anleger und versieht sie mit seiner persönlichen Meinung.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Nando Sommerfeldt über Bayers schlimmsten Börsentag, Kursverluste bei Teamviewer und wie man sich am besten von seiner Währung lossagt. Außerdem geht es um Boeing, Apple, Nvidia, YPF und den Global X MSCI Argentina ETF (WKN: A1T965). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über Buffetts Depot-Putz, Übernahmefantasie bei MediaMarkt Saturn und die richtige Geldanlage für Best-Ager. Außerdem geht es um Nvidia, AMD, Arista Networks, Palo Alto, Marathon Digital, Riot Platforms, Infineon, Siemens Energy, Target, Hellofresh, Morphosys, Xtrackers CSI300 ETF (WKN: DBX0M2), UBS Solactive China Technology ETF (WKN: A2QJ9G), HSBC Hang Seng Tech ETF (WKN: A2QHV0), KraneShares CSI China Internet ETF (WKN: A2QE7P), Berkshire Hathaway, Liberty, Sirius XM, Atlanta Braves, Celanese, Johnson & Johnson, Procter&Gamble, UPS, Mondelez, GM, SPDR S&P Global Dividend Aristocrats (WKN: A1T8GD), iShares Euro Government Bond 0-1yr (WKN: A0RGEL), Vanguard FTSE All-World Dist. (WKN: A1JX52) und Vanguard EUR Corporate Bond Dist. (WKN: A143JK). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über einen formidablen November, einen Mega-Auftrag für Airbus und eine Liebeserklärung an eine deutsche Stadt. Außerdem geht es um Zalando, Commerzbank, Deutsche Bank, Bayer, Airbus, Turkish Airlines, Continental, TSMC, United Internet, Morphosys, Plug Power, Nel ASA, Ballard Power, Bloom Energy, Thyssekrupp Nucera, Airl Liquide, Linde plc, Global X Solar ETF (WKN: A3C9MB), Global X Wind Energy ETF (WKN: A3C9MA). BNP Paribas Easy ECPI Global ESG Hydrogen (A3DDSN), Amundi Global Hydrogen ESG Screened ETF (WKN: A1C7AK), Global Hydrogen ESG Screened ETF, L&G Hydrogen Economy (A2QMAL). Invesco Hydrogen Economy (A3DP7T), VanEck Hydrogen Economy (A2QMWR) Global X Hydrogen (A3E40P), ETC Group Physical Bitcoin (WKN: 27Z30). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In dieser XXL-Sommer-Episode – einer deutsch-ungarischen Co-Produktion – berichtet Holger Zschäpitz aus dem Urlaub von den jüngsten Orban-Eskapaden und dem Nutella-Preis am Plattensee. Außerdem debattieren die beiden Finanzjournalisten Dietmar Deffner und Zschäpitz ihre eigenen Aktien-Investments und der „King of Technoschrott“ verrät weitere seiner Zocker-Positionen. Weitere Themen: - Aus Twitter wird X – welchen Markenwert Elon Musk vernichtet hat und warum sich Zschäpitz jetzt wie der Pornokönig fühlt - Aus Twitter wird X – welchen Markenwert Elon Musk vernichtet hat und warum sich Zschäpitz jetzt wie der Pornokönig fühlt - Illiberale Demokratie – Warum die Buchläden in Ungarn bestimmte Buch-Cover einwickeln müssen - Megatrend Wasser – welche Aktie vom steigenden Wasserpreis profitieren sollte - Freyr, Fluence, Enovix – warum Deffner diese Energiespeicher- und Batterie-Aktien hält - Markforged Holding – Deffners 3D-Aktie, die sich zuletzt verdoppelt hat - Li-FT Power – Was für den zockigen Minenwert spricht - Meta und Microsoft – warum die Big-Tech-Werte nach der jüngsten Rallye langfristig noch Potenzial haben - Morphosys und Medigene – warum diese beiden Biotech-Firmen in den DuZ-Depots stecken - Münchener Rück – was Zschäpitz an diesem Versicherer findet  Es gibt eigene Hoodies für "Deffner&Zschäpitz"-Fans. Einfach hier bestellen: www.welt.de/hoodie Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutzerklärung: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Daniel Eckert über Teslas ehrgeizige Pläne, die Überflieger-Aktien des Sommers und Luxus-Probleme in China. Außerdem geht es um LVMH, Hermès, Richemont, Ford, Paramount Global, Rivian, AT&T, Verizon, Morphosys, Delta Air Lines, American Airlines, Lufthansa, Air France-KLM, Southwest Airlines, iShares MSCI World EUR Hedged ETF (WKN: A1C5E7) und iShares Core MSCI World ETF (WKN: A0RPWH). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Dave Johnson, Managing Partner at Caligan Partners, makes his second appearance to discuss his thesis on MorphoSys AG (FSE: MOR; NASDAQ: MOR), including: history of the company, change in business strategy from a royalty play to traditional biotech, Pelabresib clinical trials for Myelofibrosis indication and more! For more information about Dave Johnson and Caligan Partners, please visit: https://www.caliganpartners.com/ Chapters: [0:00] Introduction + Episode sponsor: Stream by Alphasense [1:47] What is MorphoSys $MOR and why is it so interesting? [9:58] How and why Caligan Partners got involved in $MOR [19:34] What is Pelabresib and why Dave/Caligan are excited about this with regard to $MOR [27:27] Clinical trial enrollment for Pelabresib / Constellation Pharmaceuticals acquisition [33:09] Next steps for Pelabresib [36:04] Dave's thoughts on the timing of Pelabresib being approved (if approved) [38:25] Pressure on biotech management teams from boards to get deals done [40:56] Probability of success of Pelabresib and how do you value $MOR as a result [47:16] Constellation Pharmaceuticals acquisition process [50:25] Buying back convertible bonds and why that was an accretive transaction [52:55] Final thoughts on $MOR Today's episode is sponsored by: Stream by Alphasense Are traditional expert calls in the investment world becoming obsolete? According to Stream, they are, and you can access primary research easily and efficiently through their platform. With Stream, you'll have the right insights at your fingertips to make the best investment decisions. They offer a vast library of over 26,000 expert transcripts, powered by AI search technology. Plus, they provide competitive rates on expert call services, and you can even have an experienced buy-side analyst conduct the calls for you. But that's not all. Stream also provides the ability to engage with experts 1-on-1 and get your calls transcribed free-of-charge—all for 40% less than you would pay for 20 calls in a traditional expert network model. So, if you're looking to optimize your research process and increase ROI on investment research spend, Stream has the solution for you. Head over to their website at streamrg.com to learn more. Thanks for listening, and we'll catch you next time. For more information: https://www.streamrg.com/

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über den Wipe out bei Tech-Werten, einen neuen Wettlauf bei Impfstoffen und den neuen Bayer-Chef. Außerdem geht es um Nvidia, AMD, Broadcom, Tesla, Netflix, Servicenow, Marvell, Microsoft, Alphabet, Salesforce, Crowdstrike, C3.AI, Okta, ZIP Recruiter, Savannah Resources, Pfizer, GSK, Roche, Morphosys, Ford, Tesla, Aroundtown, TAG Immobilien, LEG, 2G Energy, OEssur und Datalogic.

In the field of statistics, we need specific skills necessary for being successfull. Debarshi Dey, currently the head of the Statistics and Programming and Data Management department at Morphosys, has spent the past 13 years in the pharmaceutical industry. With a PhD in statistics from UC Riverside, Debarshi believes that to be a "killer statistician," one must adopt the roles of a detective, lawyer, and storyteller. Debarshi and I discuss these key characteristics that make a statistician effective. We also explore these key takeaways from our conversation:

Episode #594 vom 06.04.2023 Den Podcast als Newsletter kriegen? Komm in die Gruppe! Inflarx macht auf BioNTech, Morphosys macht auf erfolgreich und Bernard Arnault macht auf superreich. Außerdem gehört der Telekom mehr als die Hälfte von T-Mobile, die Lufthansa hat kein Catering, Ralph Lauren liebt Krypto und die Miami Heats nicht mehr. Die zweitwertvollste Firma Brasiliens heißt Vale (WKN: A0RN7M), hat Probleme mit Eisenerz, Profite mit Nickel und Rendite mit Dividende. Ethereum goes Shanghai. Aber wohin geht der Kurs? Diesen Podcast vom 06.04.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Philipp Vetter über ein neues Wort im Siemens-Wörterbuch und Twitter-Zoff um Teslas Zahlen. Außerdem geht es um Siemens Energy, Tui, Adidas, SAP, Microsoft, Alphabet, Facebook, HelloFresh, Nagarro SE, Morphosys, Varta, Aroundtown, Gerresheimer, ProSiebenSat1, Flatex, Encavis, Xtrackers S&P 500 Inverse Daily Swap (WKN: DBX1AC), Lyxor Daily ShortDAX x2 (WKN LYX0FV). GraniteShares 1x Short FAANG Daily ETP (WKN: A3GXA3). Die Liste der Favoriten der Shortseller findet ihr hier: https://shorteurope.com/most_shorted_companies_all.php?country=germany Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über Profite bei Porsche, einen frechen Finanzinvestor und böse Kursverluste bei Buzzfeed. Außerdem geht es um Commerzbank, Deutsche Bank, Deutsche Post, Lufthansa, Fraport, Synlab, Sanofi, Pfizer, Seagen, Morphosys, Marathon Digital, Bitcoin, Banko Sabadell, Unicredit, Silicon Valley Bank, Signature Bank, First republic Bank, Keycorp, Truist Financial, US Bancorp, ARK Innovation (WKN: A14Y8H), Charles Schwab. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Diffuse Large B-Cell Lymphoma or DLBCL is the most common type of lymphoma. Much progress has been made in treatment of the disease lately, particularly with emergence of CAR T-cell therapy, but not all patients are benefiting from it. This episode of Cancer Topics features Drs. Loretta Nastoupil and Chijioke Nze exploring treatment approaches for two cases of refractory DLBCL: a 60-year-old man with no comorbidities (1:30) and a 39-year-old woman with HIV (18:35). The guests also discuss improving patient access to CAR T-cell therapy and managing its toxicities (10:35), as well as emerging therapies for DLBCL (14:30). To learn more about management of refractory DLBCL, check out the ASCO course linked bellow. Guest Disclosures:Loretta Nastoupil, MD: Honoraria – Gilead Sciences, Novartis, Bayer, Janssen Oncology, TG Therapeutics, Bristol-Myers Squibb, ADC Therapeuitcs, Morphosys, Epizyme, Genmab, Takeda, Genentech/Roche; Research Funding – Janssen Biotech, Celgene, Genentech/Roche, Epizyme, Novartis, IgM Biosciences, Caribou Biosciences, Gilead Sciences, Allogene Therapeutics, Takeda Chijioke Nze, MD, MPH: No Relationships to Disclose Resources: ASCO Course: Second-line Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma (Free to Full and Allied ASCO Members) ASCO Podcast: Cancer Topics - New Therapies for Lymphoma (Part 1) ASCO Guideline: Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor (CAR) T-Cell Therapy ASCO Article: Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma If you liked this episode, please follow the show. To explore other educational content, including courses, visit education.asco.org. Contact us at education@asco.org.  TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Loretta Nastoupil: So, I do have optimism that as we have more and more treatment options entering into the treatment landscape, we'll have fewer patients that are experiencing a refractory disease, and potentially succumbing to the lymphoma. Hello, my name is Dr. Loretta Nastoupil, I'm an Associate Professor and Deputy Chair of the Department of Lymphoma and Myeloma, at the University of Texas MD Anderson Cancer Center. Welcome to this ASCO Education podcast episode. It's my pleasure to welcome Dr. Chijioke Nze. Dr. Chijioke Nze: Hello, everyone. I'm Dr. Chijioke Nze, a Hematology/Oncology fellow at MD Anderson, I'll be co-hosting this episode with Dr. Nastoupil. Dr. Loretta Nastoupil: We've seen notable advances in diffuse large B-cell lymphoma research lately, with novel treatments including CAR T-cell therapy, offering the prospect of long-term remission for some patients, yet many patients are not even receiving second-line or later therapy, and even fewer are treated beyond the second line. How do you approach a patient with refractory diffuse large B-cell lymphoma? In today's episode, we'll explore strategies for management of refractory diffuse large B-cell lymphoma through two patient cases. So, Dr. Nze, walk us through our first case. Dr. Chijioke Nze: Our first case is Frank. Frank is 60 years old and has no comorbidities. He presented with severe back pain in September 2021, and was evaluated locally. He had a CT scan that showed retroperitoneal mass, prompting further evaluation. He had a biopsy of the left retroperitoneal mass in November 2021, which was consistent with diffuse large B-cell, germinal center B-cell of phenotype Ki-67 of 90%. He had a subsequent PET-CT scan, which showed a large conglomerate, and invasive left retroperitoneal hypermetabolic mass with satellite nodularity and contiguous bulky retroperitoneal adenopathy. He had bulky, FDG-avid metastatic retrocrural and intrathoracic adenopathy as well. He was treated with R-CHOP for six cycles, and at the end, achieved complete remission. He had a PET-CT a year later that showed new and worsening intensely FDG-avid abdominal adenopathy. This was new from a PET scan he'd had in January 2022 of the same year. He had a biopsy of this retroperitoneal adenopathy, which was consistent with relapsed diffuse large B-cell germinal center phenotype, also Ki-67 of 90%. Locally, he was treated with ICE, times five cycles, and had a follow-up CT scan at the end, which showed persistent bulky nodal disease with periaortic regional nodes with double 5, consistent with persistent disease. He also was found to have new and more conspicuous nodes in other areas as well. He presented for his first visit at MD Anderson in September 2022. Dr. Nastoupil, when you see a patient like this coming into your clinic, what's your typical approach? Dr. Loretta Nastoupil: For a diffuse large B-cell lymphoma, we are always hoping for cure with frontline rituximab, containing anthracycline-based chemotherapy. And so, it's always a gross disappointment when patients experience relapse. The timing of that relapse right now informs our current approach. And the reason I mention that, is because there have been three large randomized studies conducted and reported out just in the last year demonstrating that CAR T-cell therapy is the preferred option for patients who experience either primary refractory disease, or relapse within 12 months. And that is because they resulted in better outcomes than standard salvage-based chemotherapy and high-dose therapy autotransplant in the setting of chemosensitive disease. I have to acknowledge, of the three studies that were done, two were positive trials, so that's why currently, we have axi-cel or Axicabtagene ciloleucel, or Lisocabtagene maraleucel, and not tisa-cel or Tisagenlecleucel, as CAR T-cell therapy options. And again, that's because two of the three studies were positive trials. Now, the challenge is why would we have two positive studies in one negative trial? There are a lot of caveats to how those studies were conducted, but I think one of the biggest important lessons to be gained is that if you're going to consider CAR T for these high-risk patients, you want to do it as soon as possible, because that delay from identifying CAR T as a preferred option to actually infusing cells in a disease-- in a case particularly like this, where patients may have bulky, aggressively-behaving disease - that prolonged time may actually have an impact on outcomes. Dr. Chijioke Nze: Excellent. Thank you. So, you've mentioned he had an early relapse. How would you define early relapse in this patient population? Dr. Loretta Nastoupil: Thinking back to how we've been approaching diffuse large B-cell lymphoma over the last two decades, the PARMA study, which was done prior to Rituximab, suggested that for patients who had chemosensitive disease to a platinum-based salvage chemotherapy, which generally, was at least a partial response on CT, if they went on to high-dose therapy autologous stem cell transplant, 50-60% of those patients could anticipate cure. Whereas for the folks who continued on salvage chemotherapy, 10-20% of those patients had favorable outcome. So, we generally do try salvage-based chemotherapy, and for patients with chemosensitive disease, go on to high-dose therapy autotransplant. However, in the modern era where we've approached patients who've had rituximab as part of their frontline therapy, at least two studies - the ORCHARD study, and the CORAL study suggested that only 20% of patients who relapse in the post-rituximab era, particularly within 12 months, were successfully salvaged with platinum-based chemotherapy and high-dose therapy autologous stem cell transplant. Now, fortunately for patients who fail salvage, we have had CAR T-cell therapy as an option based off of three pivotal phase II studies, demonstrating about 40% of patients could anticipate a cure with CAR T-cell therapy. So, it only made sense to try and move that therapy up into second line, and the preferred population was those that had progressed within 12 months of frontline rituximab and anthracycline-based chemo. Now, to qualify for those studies, patients had to be considered fit for the control arm, which was salvage and auto transplant. Nonetheless, I do think for a patient like this, who's 60, without any other significant comorbidities, whose biggest challenge to longevity of life is his aggressive lymphoma, CAR T-cell therapy should be considered as soon as possible for this patient. Dr. Chijioke Nze: Is there still a role for high-dose therapy and autologous transplant in the new era, given the efficacy shown with CAR T-cell therapy? Dr. Loretta Nastoupil: I think there is. And the reason why I say that is, the trials that were done really did focus on the highest-risk patients, which were those with primary refractory disease or those who progress within 12 months of frontline. Now, there are patients that will have later relapse. And so, I do think for those patients, particularly those who are young and otherwise fit, should be approached first with a platinum-based salvage chemotherapy, in the setting of chemosensitive disease, proceed onto high-dose therapy and autologous stem cell transplant. Now, what do we do for those patients who have a late relapse but are otherwise older, or who have comorbidities that would make them suboptimal candidates for the high-dose therapy preceding stem cell transplant? I have a couple other options for those patients - so, there was a trial done with liso-cel for patients who were otherwise older, or not fit for intensive therapy. It's a single-arm phase II without a randomized comparison, but also demonstrated that liso-cel in second-line, later relapsed patients who are not fit for intensive therapy, resulted in comparable outcomes to what we would anticipate on that third-line or later setting. We also have other non-CAR T-cell therapy options, such as tafasitamab, which is a naked CD19 antibody, which has been combined with lenalidomide in the L-MIND study, again, for patients without primary refractory disease and who would not be appropriate candidates for intensive therapy. So, I do think we have alternative options, it's just when we look at the totality of the data right now, my conclusion is that CAR T-cell therapy, particularly for high-risk patients, is the most likely chance to result in cure. Dr. Chijioke Nze: Excellent. In a patient who we are considering CAR T-cell therapy, what are some of the short-term and long-term consequences, or toxicities that we should worry about? Dr. Loretta Nastoupil: One of the challenges right now with CAR T, and why it's still only available in specialized centers, is the acute toxicity, which is really a derivative of its mechanism of action. We take patients' own T-cells, we use a viral vector to introduce extracellular receptor, but also a co-stimulatory molecule. So, once these cells engage their antigen, sort of prime to react to that, and that can lead to pretty rapid T-cell expansion, release of cytokines, recruitment of other inflammatory cells to that tumor bed, and as a result, a large portion of patients can anticipate to experience cytokine release syndrome, which again, is the result of the activation of these T-cells, the expansion and the recruitment of other inflammatory cells. Fortunately, for most patients, this results in fever alone that can be managed with supportive measures. Occasionally, they'll have concomitant hypoxia or hypotension, and unfortunately, few patients will have significant or severe toxicity. The other toxicity that's less easily manageable or less predictable is the neurotoxicity that can vary according to patient-specific characteristics, such as age, and the amount of tumor burden, their performance status going into CAR, but even more importantly, the construct that's utilized, with highest rates of neurotoxicity associated with axi-cel. Again, likely speaking to its construct and the CD28 costimulatory domain that is unique to axi-cel. As a result of these acute toxicities, patients are required to stay within two hours of their treating center for the first four weeks, and they're also discouraged from operating heavy machinery, such as driving, for the first eight weeks following CAR T. So, I do you think this creates some barriers to access to this therapy, particularly the patients that are treated in community settings that may reside long distances from these certified CAR centers. Dr. Chijioke Nze: So, you mentioned that obviously, given the specialized care needed for the CAR T therapy, that they're kind of localized in certain sites. What are some of these issues with access that you're noticing both in the logistics of giving CAR T, and also in patient access? Dr. Loretta Nastoupil: I'm hoping we're going to address one of those issues right now, which is, education and awareness, because we've had these three randomized studies, and two being positive readouts just in the last year. It's important to get the message out that CAR T-cell therapy for high-risk early relapsed refractory large cell lymphoma patients can result in a significant improvement in event-free survival and progression-free survival over the standard of care. And so, being aware that this therapy can result in more favorable outcomes is step one. Step two is, we have to ensure that there are minimal barriers to getting those patients into these treating centers as quickly as possible. So, recognizing who delivers the care - is it your traditional stem cell transplant physician? Is it a lymphoma doctor? What centers are certified? Some of these issues can be addressed with quick internet searches. So, for instance, in our center, we have a 1-800 number for anyone who's interested in CAR T-cell therapy that connects them directly to a CAR T coordinator who can help them understand do they meet the FDA-approved indication? Would they be interested in seeking consult? And we try and prioritize getting those patients in the door as soon as possible since time likely does have an impact on outcomes. And then, partnering with our community oncologist - you're going to be the primary oncologist for these patients leading up to CAR, and then after that four-week window, when we're keeping the patients in close proximity to our centers, we often send them back. And so, making sure that they're comfortable knowing what potential late toxicities to be on the lookout for, which include B-cell aplasia and risk for infection, or prolonged cytopenias, beyond just lymphopenia. And so again, there's a need for education and partnering with our community sites to make sure that there is successful handoff of these patients back after they've completed the monitoring for the acute toxicity. And then, really trying to explore opportunities to utilize some of the better tolerated CAR T, such as liso-cel, in your non-traditional academic centers. Those that are equipped to handle phase I studies or stem cell transplant, for instance, may not be affiliated with the university. So, I think those are all types of strategies that could be employed to try and improve access for patients. Dr. Chijioke Nze: And then, you mentioned the liso-cel, but in some of the toxicities, are there ways of predicting which patients will do better or worse? Are there ways to reduce toxicities? And is there any hope for things such as outpatient administration of CAR T? Dr. Loretta Nastoupil: So, my answer today may improve over time as we get larger numbers and more experience, but what we currently understand is that the patient performance status, their degree of tumor, how quickly that tumor is increasing, LDH and some inflammatory markers such as CRP or ferritin pretreatment can provide some insight into a higher risk of toxicity. And then obviously, the construct that's utilized. Again, axi-cel has higher rates of neurotoxicity. All will have some form of cytokine release syndrome, generally speaking, but rates of grade three or higher are quite infrequent, particularly with liso-cel and tisa-cel. So, it's multifactorial. That then raises the question, can we do anything to alter those modifiable risk factors? Can we reduce the disease burden? Can we improve the performance status? Can we do anything to reduce the inflammatory markers pre-treatment? And so, those are strategies that are being discussed, and I think in general, as we get more effective therapies that enter into the treatment landscape, it's probably some of the best ways to try and reduce some of those risk factors. Dr. Chijioke Nze: Rounding that up, are there any exciting developments or things to look out for, for exciting therapies in the relapse setting? Dr. Loretta Nastoupil: A couple of things beyond CAR T that I think we should all be aware of and anticipate to be in our toolkit relatively soon; probably, one of the most exciting, is the development of the bispecific antibodies. So, another challenge with CAR T is the requirement to collect these patients' own T-cells and send them off to a central manufacturing site, and the turnaround time can be anywhere from 3-4 weeks. And again, in a situation where you have an aggressive disease, that can be a long time to wait. And so, is there any treatments that are more readily available, that again, will be effective at reducing disease burden? And so, by specifics kind of fit those unmet needs to some extent - you have essentially two heads; one head is going to bind the endogenous T-cells that eliminates the need to leukapherese these patients and manufacture, and then the other head is going to generally engage CD20, which we know is an effective targeted antigen, particularly in B-cell lymphomas. And there are a number that are under development. We saw preliminary phase II data with glofitamab, epcoritamab, as well as combination strategies with mosunetuzumab. So, I do have optimism that the bispecific antibodies will potentially enter into the treatment landscape. I anticipate they'll probably be used first post-CAR T, but will likely move their way into earlier lines of therapy. I've already mentioned tafasitamab in combination with lenalidomide, which is an effective non-chemotherapy option. We have antibody-drug conjugates, such as Loncastuximab, which is a CD19 antibody-drug conjugate. It's essentially targeted delivery of chemotherapy, and it looks to have a pretty promising activity as a single agent in that third-line or later space, and then polatuzumab, which is a CD79b antibody drug conjugate, in the relapse setting has been combined with bendamustine and rituximab, but also demonstrated significant improvement in the frontline setting in the POLARIS study where vincristine was replaced with polatuzumab. So, I do have optimism that as we have more and more treatment options entering into the treatment landscape, we'll have fewer patients that are experiencing refractory disease, and potentially succumbing to the lymphoma. Dr. Chijioke Nze: And then, one additional question: How do you approach a patient who is not quite as fit, in thinking about what their options are for later-line therapies? You already mentioned some of these, but which of those would you prioritize in this setting? Dr. Loretta Nastoupil: Again, as we get more experience, we develop skills that help us sort of navigate all these different options. In my practice, if I'm even considering CAR T, I'm going to delay bendamustine until after I've collected those cells. I think that's one caveat that-- we do get nervous about the quality of those autologous CAR Ts if they're generated in someone who's had recent exposure to bendamustine. So, that may help me sequence that later on. We have questions right now about what's the optimal sequencing of CD19-directed therapy because we have several options beyond just CAR T-- As I mentioned, we have Lonca, we've got tafasitamab and lenalidomide. Currently, we don't have prospective data that really informs that question, and there's a number of research studies underway to try and help us understand if there is a preferred sequence, or even if it matters how we handle CD19 targeting. For my older, frailer patients where I'm really worried, they're not going to be able to tolerate something like liso-cel, or they're not going to be able to have that caregiver, and they're uncomfortable relocating to an area where CAR T might be available, my general approach right now is to consider tafasitamab and lenalidomide first in that relapse setting, followed by either Lonca or Pola-BR. Selinexor is another option. It's an oral agent, though again, in my opinion, if we look at the totality of the data, may be less effective than the other options. So, I might reserve that as a last option for someone, again, with relapsed/refractory large cell. Dr. Chijioke Nze: Excellent. Thank you. This has been very helpful. Dr. Loretta Nastoupil: All right. So, Dr. Nze, now I'm going to turn the table and ask you some questions. I'm going to change this up a little bit - she's now a 39-year-old female. She has significant comorbidities. She has HIV, and again, large cell lymphoma. So, let me walk you through her case, and then we'll discuss some of the challenges, again, in a very different scenario, albeit a similar disease. So, our female is, I mentioned 39, pre-existing HIV, she's treated frontline with six cycles of R-CHOP and intrathecal methotrexate for CNS prophylaxis. Because of her comorbidities, again, not well controlled HIV, she also has a poor functional status at the time of relapse. This was a couple years ago, and CAR T was not an option in second line, though she is someone who had a relapse that was beyond 12 months. So, for her second-line approach, because of her comorbidities, she actually receives rituximab in combination with high-dose cytarabine, dexamethasone, and oxaliplatin for three cycles, and actually achieves a chemosensitive disease and is referred to our stem cell transplant colleagues. Unfortunately, at that time, due to comorbidities, she was deemed not to be an appropriate candidate for high-dose therapy, and she's been monitored for signs of relapse. Despite being in the minority, she actually does not have a recurrence of her lymphoma but has a number of other, again, challenges in regards to her comorbidity, including multiple infections, resulting in recurrent hospitalizations. And so, it's always been a challenge for me in being intimately involved in her case, deciding when she's presenting, how alarmed to be about recurrent lymphoma versus infection, and how I might approach her in the setting of relapsed large cell lymphoma. So, what role does prior type and response to therapy play in treatment selection at your next line of treatment? Dr. Chijioke Nze: I think in this patient, it sounds like she got one adequate therapy on and the initial presentation with R-CHOP, and then with IT chemotherapy as well. She looked like she had a good response. I think the fact that she achieved a complete response and the duration of her response, lets me know that she likely has chemosensitive disease. This, in turn, helps me to pick what to do next. As you mentioned previously, we know how efficacious the CAR T therapy is, but in someone like her who had a long duration, trying salvage therapy and proceeding to autologous transplant might make sense. I'd be interested in your thoughts. Dr. Loretta Nastoupil: Yeah, I agree. And I think part of the challenge, particularly when we're facing patients with HIV, they're often excluded from prospective studies. And so, we're often in a scenario where we may not have the wealth of data to inform our treatment decision. But I do think in general, comorbidities play a major role-- we're navigating treatment options. Because again, traditionally, we've used intensive chemotherapy as our mainstay of treatment, and there are clear criteria that patients generally should meet that help us predict how likely they are to have significant or severe toxicity from high-dose therapy. And this is a prime example of even though she was young, her comorbidity made her a poor candidate for intensive therapy. I think the other sort of non-clinical factors that we sometimes take into consideration, because CAR T was approved off of single-arm phase II studies, again, none of which would've included someone like her, because of her HIV status, how do we extrapolate-- for instance, if she had relapsed in that third-line space, and suggesting that she did not have significant infection or other significant comorbidities, do we have experience to proceed with an autologous CAR in that setting? So, again, there've been a few cases where we have case reports where people have reported on their standard of care outcomes, particularly with CAR T in patients with active HIV disease, but one of the concerns I have in these scenarios is very selected. If you have active infection, that can make the acute toxicity with CAR significantly worse. And so again, we're trying to navigate a sort of limited data zone to try and help her and choose the right therapy. Again, you've met this patient with me, you helped care for her for some time, and you have a unique experience of also practicing in a county hospital where comorbidities, particularly, like HIV, can be much more common. What is your perception regarding barriers to accessing CAR T as it pertains to social factors, clinical factors, and again, this is a case that highlights some of those issues. Dr. Chijioke Nze: You mentioned at first that she had uncontrolled HIV. So, I think which, one, speaks to her treatment reference of her non-malignancy-related diseases, and trying to get that under control would be one of the first things I could think about. Thinking about how her care is managed and what kind of support she has are very important for us to think about as well. The other thing that's very important is, a lot of patients who we're seeing in the community may not have access to such specialized centers such as MD Anderson, where patients do have access to clinical trials and CAR T therapy. So, patients who are unlike her, who might qualify, may not actually be able to get these therapies as well. Part of the reason is, it can be insurance status, which is what we see in a lot of our patients. So, a barrier to get into the door. And then too barriers, lack of social support can be a big issue as well. And then there's also a big push in the community to improve the trust and awareness of these novel therapies, as you've mentioned. So, in a lot of the community practice, some of the community practitioners may not be comfortable with these, and a lot of the patients may not have heard of these new technologies, and also want to defer trying new therapies before having other people try new therapies before they consider them themselves. I think all these things present specific significant barriers to patients in the community. One, their ability to adhere to care, two, their insurance and their ability to get care and the financial toxicities associated with that. And then third, really understanding the options that are available. Dr. Loretta Nastoupil: And again, just to try and illustrate a couple other points. You know, we use a case here, which is a real case, with significant comorbidities such as HIV, which again, is something that is not frequently encountered, and will have a large impact on treatment selection. What if I just told you this patient has comorbidities, but she has moderate type-2 diabetes, and as a result, she has mild renal insufficiency, ejection fraction is actually adequate, would you have done anything different in this case? Dr. Chijioke Nze: No. I think in this particular case, I do think the fact that she did have a good response for a long duration of time, and did seem to have chemosensitive disease, I would probably still have tried a salvage therapy and autologous transplant in this patient. In the event that she was refractory, or had early relapse, and in that case, I would consider her to not be chemosensitive and would definitely have sought some more active therapies such as CAR T cell therapy through available products. Dr. Loretta Nastoupil: And then one last question for you: What if we just changed her age and we made her 79, but no other significant comorbidities, how would that have impacted your approach? Dr. Chijioke Nze: I'm going to turn that one over to you, I'm not exactly sure how I would treat with older patient with the same disease. Dr. Loretta Nastoupil: That's fair. So, if you have an older patient who has a late relapse, but not necessarily someone you would consider appropriate for salvage chemotherapy and high-dose therapy, then I think tafasitamab and lenalidomide would be probably my first choice in that setting, just based off of the L-MIND study. Dr. Chijioke Nze: Thank you, Dr. Nastoupil, for a great discussion of the management of diffuse large B-cell lymphoma. And thank you to all our listeners. We appreciate you tuning in to this episode of the ASCO Educational podcast.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Laurin Meyer und Holger Zschäpitz über den tückischen Job-Motor der USA, eine Meme-Aktie vor der Pleite und eines der wertvollsten Start-ups der Welt. Außerdem geht es um Tesla, Amazon, Alphabet, Sentinel One, Cloudflare, Crowdstrike, Datadog, Snowflake, Bed Bath & Beyond, Mercedes-Benz, Morphosys, Synlab, Porsche, Adidas, Continental, Covestro, SAP, Siemens Energy, Mercedes, Allianz, BMW, Volkswagen, Deutsche Telekom, Siemens, BASF, Vonovia, iShares DivDax ETF (WKN: 263527), iShares STOXX Global Select Dividend 100 ETF (WKN: A0F5UH), Vanguard FTSE All-World High Dividend Yield ETF (WKN: A1T8FV), SPDR S&P Global Dividend Aristocrats ETF (WKN: A1T8GD), Coca-Cola, IBM, McDonald's, Apple, Microsoft, Google, Meta, Xtrackers S&P 500 Equal Weight ETF (WKN: A1106A), Haliburton, OSSIAM STOXX Europe 600 ESG Broad Market Equal Weight (WKN: A1JH12), iShares STOXX Europe 600 ETF (WKN: 263530), Roche, Novo Nordisk, AstraZeneca, LVMH, Shell, TotalEnergies und HANetf HAN-GINS Tech Megatrend Equal Weight ETF (WKN: A2JR0J). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition. Mikkael A. Sekeres, MD, MS, chief of the division of hematology and professor of medicine at Sylvester Comprehensive Cancer Center and University of Miami Health System and chair of the ASH committee on communications, discusses some key take-home points from the Long COVID presentation. :00 Shakira J. Grant, MBBS, discusses multilevel interventions required to increase the rate at which Black individuals participate in hematology research studies. 3:44 Arushi Khurana, MBBS, reviews criteria used to disqualify patients from participating in front-line clinical trials, the acceptable ranges of which often prohibited Black and Hispanic patients from enrollment. 6:35 Tatyana Feldman, MD, discusses how the addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma. 9:32 Warren B. Fingrut, MD, reviews how hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry. 12:02 Read the full coverage here: Restrictive diet an 'unnecessary burden' for patients undergoing HSCT Multilevel interventions needed to reduce racial disparities in clinical trial enrollment Eligibility criteria more likely to exclude minorities from lymphoma clinical trials Combination ‘promising' for advanced classical Hodgkin lymphoma Non-European HSCT recipients undergo more complex procedures with fewer resources Disclosures: Feldman reports consulting/advisory roles with, speakers bureau roles with or other financial relationships with AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genmab, Genomic Testing Cooperative, Janssen, Karyopharm Therapeutics, Kite Pharma, MorphoSys, Pharmacyclics, Secura Bio, Seagen and Takeda. Please see the abstract for all other researchers' relevant financial disclosures. Fingrut reports no relevant financial disclosures. Please see the abstract for all other researchers' relevant financial disclosures. Grant reports no relevant financial disclosures. Please see the abstract for all other researchers' relevant financial disclosures. Khurana reports no relevant financial disclosures.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Laurin Meyer über teure Rabatte bei Mercedes, den Trump-Effekt bei den sozialen Netzwerken und den richtigen Kaufrhythmus fürs Depot. Außerdem geht es um Walmart, Target, Micron, Volkswagen, BMW, Morphosys, Curevac, Bitcoin, Ethereum, Siemens Energy, Meta, Bumble, Pinterest, Twitter, Digital World Acquisition, Phunware, Rumble und Remark Holdings. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Laurin Meyer über unverhofftes Lob für Netflix, den Luxus-Kauf bei Estée Lauder und Blackout-Aktien fürs Depot. Außerdem geht es um Taiwan Semiconductor, Nordex, Home Depot, Macy's, Danone, Campbell Soup, Kimberly-Clark, SQM, Generac, American Outdoor Brands und Morphosys. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Der DAX steigt, denn Infineon boomt. Morphosys verliert derweil die große Alzheimerhoffnung und Rheinmetall einen Konkurrenten. Apropos Verluste: Die gibt's auch bei Oatly, der Mitarbeiterliste von Amazon und dem Konto von Jeff Bezos. Mit den Produkten von Cherry (WKN: A3CRRN) kann man nicht nur zocken, sondern auch Krankenkarten lesen. Das ist gut, denn Zocken will grad keiner. Genau wie die Aktien von Cherry. Vielleicht sollte man aber wollen. Thomson Reuters (WKN: A2N94N) hat die größte Nachrichtenagentur der Welt. Geld machen die Kanadier aber mit langweiliger, wiederkehrender und profitabler Software. Diesen Podcast der Podstars GmbH (Noah Leidinger) vom 15.11.2022, 3:00 Uhr stellt Dir die Trade Republic Bank GmbH zur Verfügung. Die Trade Republic Bank GmbH wird von der Bundesanstalt für Finanzaufsicht beaufsichtigt.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die britische Notenbank als Kavallerie der Märkte, die Gaspreisdeckel-Klatsche für Energiefresser und frischen Wind fürs Depot. Außerdem geht es um Porsche, Biogen, Eisai, Roche, Morphosys, Eli Lilly, ThyssenKrupp, Salzgitter, Commerzbank, Deutsche Bank, Apple, VW, Glencore, Ginkgo Bioworks, Invitae, Twist, 10x Genomics, Uipath, Invesco Wind Energy (WKN: A3DP7S), Global X Wind Energy (WKN: A3C9MA), Orsted, Siemens Gamesa, Vestas, Boralex, Axiona Energias Renovables, Ming Yang Smart Energy, SGL Carbon, SKF, Encavis, Energiekontor und Brookfield Renwable. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ berichten die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über das Spektakel bei der Prosus-Aktie und einen neuen Strohhalm für Nordex. Außerdem geht es um Delivery Hero, Tencent, Morphosys, Robinhood, iShares Global Infrastructure (WKN: A0LEW9), SPDR Morningstar Multi-Asset Global Infrastructure (WKN: A12EAR) Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++Werbung+++ Hier geht's zur App: Scalable Capital ist der Broker mit Flatrate. Unbegrenzt Aktien traden und alle ETFs kostenlos besparen – für nur 2,99 € im Monat, ohne weitere Kosten. Und jetzt ab aufs Parkett, die Scalable App downloaden und loslegen. Hier geht's zur App: https://bit.ly/3abrHQm Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ berichten die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über schlechte Nachrichten, die für gute Laune sorgen, eine Überraschung bei Tui und die Deals des G7-Gipfels. Außerdem geht es um United Airlines, Royal Carribean, Norwegian Cruise Line, Carnival, AirBnB, Tui, Zendesk, SAP, Adidas, Delivery Hero, Allianz, Siemens, Bayer, Lufthansa, BASF, Hellofresh und Deutsche Post. Morphosys, Adler Group, Varta, Home24, FlatexDegiro, SMA Solar, Shop Apotheke, Deutsche Lufthansa, Westwing, Nordex. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++Werbung+++ Hier geht's zur App: Scalable Capital ist der Broker mit Flatrate. Unbegrenzt Aktien traden und alle ETFs kostenlos besparen – für nur 2,99 € im Monat, ohne weitere Kosten. Und jetzt ab aufs Parkett, die Scalable App downloaden und loslegen. Hier geht's zur App: https://bit.ly/3abrHQm Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Dr. Sonali Smith, of University of Chicago Medicine, highlights dynamic sessions and hot topics that will be featured in the 2022 ASCO Annual Meeting Scientific Program, including practice-changing advances in breast cancer, colorectal cancer, sarcoma, and myeloma.     Transcript  ASCO Daily News: Hello and welcome to the ASCO Daily News podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. I'm delighted to welcome Dr. Sonali Smith, professor and chief of the hematology-oncology section at University of Chicago Medicine.  Dr. Smith is also the Chair of the 2022 ASCO Annual Meeting Scientific Program and joins me to discuss the hot topics and must-see sessions that will be featured at the meeting.  Her full disclosures are available in the show notes and disclosures relating to all guests on the podcast can be found on our transcripts at asco.org/podcasts.  Dr. Smith, it's great to have you on the podcast today.  Dr. Sonali Smith: Thank you, Geraldine. It's a pleasure to be here.  ASCO Daily News: Well, thousands of abstracts were submitted for consideration this year and more than 2,900 were selected for presentation. We'll talk about some of the must-see sessions. First, can you tell us about the areas that have shown tremendous advances this year—the practice-changing abstracts that will make the headlines?  Dr. Sonali Smith: Yes, that's right. There were over 6,000 abstracts submitted for consideration this year and more than 2,900 abstracts were selected for presentation with over 250 oral presentations. We had 2,200 that were online publication only. And given the hybrid nature of ASCO [Annual Meeting] this year, we will have 86 sessions that will be livestreamed, including all of our abstracts that are oral.  I'm really excited about the Plenary. In particular, there are going to be some practice-changing abstracts involving breast cancer, colon cancer, sarcoma, and myeloma. We are really thrilled with the quality and the excitement around the data and I do think this is going to be very important for people who are in practice.  When we think about the different abstracts that have been submitted for the Plenary, they will focus on front-line colon cancer, the approach to Ewing sarcoma in pediatric patients, and the use of antibody-drug conjugates for breast cancer in a very specific subset. And then also some discussion about, or presentation about, the use of maintenance therapy in patients with myeloma.  ASCO Daily News: Excellent. Well, the Clinical Science Symposia are quite popular among participants. Can you tell us about some of the topics that will be featured this year?  Dr. Sonali Smith: Yes. So, the Clinical Science Symposia (CSS) were really a lot of fun to pull together. As this audience knows well, this is an opportunity for us to take a look at all of the abstracts submitted and look for cross-cutting themes between all of the different cancers that we take care of. They can focus on new technology. They can focus on new approaches to therapy. And after looking at all of the submitted data, we have 3 really outstanding special Clinical Science Symposia for which I'm really excited.  One is going to focus on circulating tumor DNA, “ctDNA: Dawn of a New Era,” and I really do believe in that title and encourage everybody to come and hear how this could be applied in practice.  The second special CSS will be on Bispecifics. Really asking the investigators as well as the discussants. “Bispecifics: Are Two Better Than One?” And then the third special Clinical Science Symposium will be called, “Is There a Ghost in the Machine? Putting Artificial Intelligence to Work.” And as many of us know, machine learning is finally finding its way into oncology. And I'm just thrilled at the abstracts that have been submitted.  I also just wanted to say that we've had a really outstanding speaker lineup and it's incredibly diverse with international perspectives brought to the table.  ASCO Daily News: Absolutely. And so, what are some of the other sessions that will be on your own list this year?  Dr. Sonali Smith: Well, I'm really excited about the opening session, which will be at 9:30 in the morning on Saturday, June 4th. We will have our president, Dr. Everett Vokes, speaking on his theme, Advancing Equitable Cancer Care Through Innovation.  We also have our FASCO presentations, and we have 2 special speakers. One will be Ned Sharpless, who is the head of the National Cancer Institute. And then we will also have Dr. Andre Ilbawi, who is the lead of cancer programs at the World Health Organization. He has had an incredible impact on improving access for children with cancer on a global level. And I think this series of speakers really fits with our theme this year.  Another session I'm really looking forward to is the [David A.] Karnofsky [Award and] lecture by this year's widely respected speaker, Dr. Jedd Wolchock. This is anticipated to be an incredibly thought-provoking and clinically relevant presentation, and I hope all of you will join us.  ASCO Daily News: In following up then on the theme of the meeting this year, it is, of course, Advancing Equitable Cancer Care Through Innovation, can you comment on how important it is that this theme is represented in as many of these programs, as many of these sessions as possible at meetings such as the [2022] ASCO Annual Meeting and other symposia?  Dr. Sonali Smith: A global approach and a global mentality when we are developing therapies, preventive approaches, are really incredibly important. In the United States, at least, the survival for patients with cancer has doubled, and I think it is really important to remember that we are a global organization and there are many people around the world who can benefit. And if we can put innovation into this, hopefully, it can be done better and faster.  ASCO Daily News: Absolutely! Well, thank you so much, Dr. Smith, for taking the time to be on the podcast today and for sharing some of these highlights. And a big thank you for your efforts to create a really robust scientific program for the 2022 ASCO Annual Meeting.  Dr. Sonali Smith: Thank you so much. It's been a real pleasure.  ASCO Daily News: And thank you to our listeners for your time today. If you're enjoying the content on the ASCO Daily News podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.      Disclosures:   Dr. Sonali Smith has been paid for any consulting or advisory role by ADC Therapeutics , Adaptive Biotechnologies , Gilead Sciences, Bristol Myers Squibb, MorphoSys, Janssen, Bantam Pharmaceutical, and Karyopharm Therapeutics, currently or during the past 2 years. Dr. Smith has received research funding from Portola Pharmaceuticals, Genentech, Acerta Pharma, Pharmacyclics, Celgene, Curis, Bristol Myers Squibb, TGTX, Merck, Forty Seven, and Novartis, currently or within the past 2 years.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   

Dr. John Sweetenham, of the UT Southwestern's Harold C. Simmons Comprehensive Cancer Center, and Dr. Marc Braunstein, of NYU Langone Health, discuss key data from the CAPTIVATE and GRIFFIN trials and other compelling studies in hematologic malignancies featured at the 2022 ASCO Annual Meeting.  Dr. John Sweetenham: Hello. I'm John Sweetenham, the associate director for Clinical Affairs at UT Southwestern Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News podcast.  For my guest today, I'm pleased to introduce Dr. Marc Braunstein, a hematologist, and oncologist at NYU Perlmutter Cancer Center. We'll be discussing key posters on advances in hematologic malignancies that will be featured at the 2022 ASCO Annual Meeting.  Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcripts at asco.org/podcasts.  Marc, it's great to have you on the podcast today.  Dr. Marc Braunstein: Thank you, John. It's a pleasure to be here.  Dr. John Sweetenham: So, Marc, there are going to be some very interesting abstracts with some provocative results presented at the ASCO Annual Meeting this year. I know we've selected a number of these to speak about today, beginning with Abstract 8027 on the subject of multiple myeloma. And this I think is a long-term follow-up study for long-term survivors of multiple myeloma more than 12 years out now. Can you comment on this and let us know what you believe the key takehomes from this study are?  Dr. Marc Braunstein: Sure. Absolutely, John. So, this was a prospective registry that has been in place since 2009, and it's composed of various practice settings, but primarily community practices where most patients get their myeloma care. And what they did was they looked at about 1,400 patients with newly diagnosed multiple myeloma across 250 sites in the U.S. between 2009 and 2011 who were included in the registry. The participants also filled out the quality-of-life surveys, and they compared a group of long-term survivors who had more than 8 years of follow-up to patients who were not long-term survivors below that 8-year threshold.  So, about 20% were in the long-term survival group and 80% in the non-long term survival group. And they basically characterized those 2 groups. What they found was that the individuals who did have long-term survival were generally younger—median age of 62 versus 68, and had better performance status, were more likely to receive stem cell transplants, about 66 versus 60%.  And therefore, the implication of this is that patients who fit those criteria may have a better prognosis in addition to the other cytogenetics and other factors we use as prognostic indicators. And what was also interesting was that the 8-year overall survival of the overall group was about 36%.  So, we still have room to go in terms of bringing new therapies to extend survival in this condition. And only 20% of the total population were long-term survivors at that 8-year threshold. So, those were the general findings of the abstract.  Dr. John Sweetenham: Do you think it gives us new information on patient selection for more intensive therapies upfront?  Dr. Marc Braunstein: Well, I think it certainly tells us which patients are more likely to have longer-term survival. I think we know in multiple myeloma that it's essential to really use the patient's presenting features, their disease features, their comorbidities, and their degree of fitness or frailty to guide how intensive a therapy or regimen we can devise for that individual patient. But I think it certainly says that if you have a patient who is on the younger side of the spectrum, who is eligible for stem cell transplant, who has a better performance status, those are the patients that are more likely to have the long-term survival. It doesn't necessarily say that if you're not in that category, you won't have long-term survival, but on average, those were the patients who fared better in the long term.  Dr. John Sweetenham: Okay. So, staying for a little while on the subject of multiple myeloma, Abstract 8037 is really addressing a very different question. It's the application of circulating tumor DNA analysis and its association with relapse in patients with refractory myeloma. Would you comment a little on this and maybe let us know what you think the significance of this will be for the future?  Dr. Marc Braunstein: Sure. My colleagues in the solid tumor space are using circulating tumor DNA regularly and in the myeloma field, we're a little bit jealous of them.  So, it's helpful to have a study like this that's looking at circulating peripheral blood markers, in this case circulating tumor DNA, to help guide various prognostic or predictive indices that will help us guide therapeutic decisions.  So, this was a study where they looked at patients who were enrolled in a phase 2 study of a free-drug regimen of carfilzomib-thalidomide-dexamethasone the MM17 study, and they took 50 transplant eligible multiple myeloma patients who were refractory to their first line of therapy, and they collected bone marrow samples and peripheral blood at 3 time points at the third cycle of treatment and at the end of the study or at the point of refractoriness to that regimen.  They collected about 187 samples in total. They used a sequencing technique to determine the variance of 22 gene signatures known to be mutated in multiple myeloma. And what they found was a particular gene signature that was associated with shorter progression-free and overall survival in that phase 2 study. And those genes included known oncogenic drivers, including BRAF genes, ATM, and P53.  What was particularly interesting among the circulating tumor DNA mutations was that they were found in about 88% of patients at the start of the study. So, what that tells us is, number 1, circulating tumor DNA offers a wealth of information that can be highly valuable in multiple myeloma, which is a disease where we typically rely on the bone marrow to assess the status of the plasma cells and status of the mutation profile.  And number 2, that many of these mutations may be present earlier on in a disease that we know evolves in a clonal way that leads to disease progression. So, I think there's still a lot of information we have to learn about the utility of circulating tumor DNA in myeloma, but this study certainly shows that there's a lot to be explored in terms of the mutational profile and peripheral blood in myeloma.  Dr. John Sweetenham: A couple of questions that arise for me out of this study. First of all, do you think this is going to have any implications for future study design and patient selection?  Dr. Marc Braunstein: Definitely. I think the whole field in multiple myeloma is progressing quickly in terms of how we assess response, how we use minimal residual disease, and moving more towards using novel markers in peripheral blood, including mass spectrometry, and now perhaps circulating tumor DNA to look at surrogate markers for survival.  And so, what this abstract is showing is that we could potentially use circulating tumor DNA both as prognostic markers, potentially as disease response markers, and prognostic markers to guide which patients may be more likely to have shorter survival. So, I think this has a lot of implications for how we design future studies.  Dr. John Sweetenham: Yeah. And the second question, do you think this is the beginning of the end of bone marrow analysis in multiple myeloma?  Dr. Marc Braunstein: So, I can tell you if it is, patients I think will be very happy and so will clinicians because we really want to know at the core what the degree of residual disease is in a patient. And right now, the only way to do that is through a bone marrow biopsy.  And so, I think that this is the beginning of the use of peripheral blood studies with higher resolution to allow us to gain more information on patients that hopefully will allow us to obviate the need for more invasive testing like bone marrow biopsies.  Dr. John Sweetenham: Yeah, absolutely. Thanks. Just changing gears now, moving on to Abstract 7050. This is an abstract that addresses what I think we'd all agree is becoming an increasingly important question in the management of chronic myeloid leukemia (CML), and that is number 1, is it safe to discontinue therapy in responding patients? And number 2, when is it safe to discontinue that therapy?  Dr. Marc Braunstein: So, this is an abstract that is looking primarily at CML. You know that we're making a lot of progress when we can begin to talk about discontinuation and de-escalation of therapy.  And so, in the field of CML, the use of tyrosine kinase inhibitors (TKIs) and the targeting of the BCR-ABL mutation has brought about tremendous progress in patients in the chronic phase.  So, there have been several retrospective studies that have looked at the role of discontinuing one of the TKIs. Most of the studies have focused on imatinib since that was the first one that was discovered, but they've looked at others in the class as well.  What struck me the most is that there's a remarkable consistency between these studies. So, when you discontinue one of these TKIs, the percentage of patients who remain in remission is somewhere between 40 to 50%. And what this abstract looked at was a single institution retrospective assessment of 284 patients with CML, between 1999 and 2017, who were treated with a TKI for their CML and then subsequently discontinued the therapy.  Now, what's worth noting in the various studies that have looked at discontinuation therapy is that patients who were taken off of the TKI generally were in a good molecular remission, MR 4 or 4.5, for at least 2 or 3 years. And in this study, about 70% of patients had electively discontinued and 24% of patients stopped due to adverse events.  So, it wasn't necessarily guided by their response to treatment at the time of discontinuation. What they found actually was fairly consistent with the literature that at a median follow-up of 36 months after TKI discontinuation, about 19% lost their molecular remission and 88% had achieved a molecular remission after resuming therapy. And that is consistent with the literature that fortunately, even if a patient loses their molecular remission off of the TKI therapy, the majority of patients will go back into molecular remission when you re-challenge them.  Dr. John Sweetenham: Important data, indeed. And you know, on something of a similar theme, the next abstract that we're going to look at is the Abstract 7519. In this case, in chronic lymphocytic leukemia (CLL), and certainly, those of us who remember when ibrutinib was initially introduced into the second-line treatment of CLL, didn't really know whether discontinuation or fixed duration treatment with agents like this was going to be something that we could pursue or whether treatment with these drugs was going to be indefinite. This abstract certainly addresses that specific question, and again, I'm interested in your insights into this.  Dr. Marc Braunstein: Sure. So, this is an abstract looking at CLL, where we've really begun to move away from chemotherapy, and we have a variety of targeted oral therapies that target the underlying pathology of this leukemia.  And so, as you mentioned, ibrutinib is approved both in the relapsed and more recently in the frontline setting, wherein the RESONATE-2 study that was published in the New England Journal of Medicine in 2015, there was actually an overall survival benefit of ibrutinib even in higher-risk patients.  So, the CAPTIVATE study is an ongoing phase 2 study that is looking at whether we can improve the efficacy of single-agent ibrutinib in the first-line setting when combined with venetoclax.  Ibrutinib targets protein tyrosine kinase and venetoclax targets Bcl-2, and that combination is hypothesized to further weaken the resistance of CLL and lead to better outcomes.  So, this was a multicenter phase 2 study. And in this abstract, they looked at the 3-year follow-up of patients who were actually able to discontinue therapy on this regimen. So, just as a bit of background, ibrutinib is typically continued until progression, and venetoclax as it's been studied in the first-line setting with obinutuzumab is given for about 12 months.  So, in this study, at 3-year follow-up, they looked at the patients in the cohort who were off therapy and looked at the percentage of patients who maintained a complete remission at 3 years. And that complete remission rate was about 57%.  The majority of patients, greater than 95% of patients, were alive at 3 years even in the high-risk cohort. So, I think the implications of the study is that upfront or oral targeted therapies when you combine ibrutinib and venetoclax really produce tremendous responses that are durable, and it's found even in the high-risk patients who are expected not to do quite as well at 3 years.  Dr. John Sweetenham: Yeah, I agree. I think it's very reassuring actually to see these durable responses with this fixed duration regimen. And to conclude, Abstract 8011 was an abstract which addressed treatment in the first-line setting for multiple myeloma. And again, I wonder if you could comment on this study.  Dr. Marc Braunstein: Sure! So, this is a study looking at the GRIFFIN regimen, which was a phase 2 randomized study of daratumumab (DARA), plus lenalidomide, bortezomib, and dexamethasone.  So, DARA RVd versus RVd alone. In that study, the primary endpoint was stringent, complete remission, and it has been previously presented and published that the stringent complete remission (CR) rate was significantly improved, 42% versus 32%, when you include daratumumab upfront.  In this abstract, they looked at the sustained rate of minimal residual disease negativity, which is basically the deepest possible remission you can achieve in upfront therapy and in myeloma.  What they found was that, again, when you looked at the quadruplet regimen versus the triplet regimen, the rates of minimum residual disease (MRD) negativity were just improved with the quad regimen.  So, at a median follow-up of 38.6 months, there were about 54 versus 20% of patients who were MRD negative at 12 months amongst the patients who had achieved a CR, and 59 versus 17% MRD negative among the patients who achieved a stringent CR favoring the daratumumab arm.  So, I think this abstract shows the benefit of including a monoclonal antibody upfront in newly diagnosed patients with myeloma combined with stem cell transplant and maintenance, allowing for sustained MRD negativity.  Dr. John Sweetenham: Do you think this represents a new standard of care?  Dr. Marc Braunstein: I do. At our institution, we've adopted this regimen for most newly diagnosed transplant-eligible patients. I think the data clearly show an improved depth of response and MRD negativity rates, and I think that there are a number of ongoing studies looking at the role of monoclonal antibodies in the maintenance phase as well.  I'm especially excited this year, at ASCO Annual Meeting there's a plenary session involving myeloma looking at patients who received RVd upfront and then went for transplant. But I think we can improve on that regimen by including monoclonal antibodies and immunotherapies upfront, and I do think it represents a new era of immunotherapies in multiple myeloma.  Dr. John Sweetenham: Well, thanks, Marc. I mean, to your last point, it sounds as if there is a lot, including these abstracts, to look forward to at the upcoming ASCO meeting. So, we really appreciate you sharing your insights into these abstracts with us today.  Dr. Marc Braunstein: Sure. My pleasure. Thank you for having me, John.  Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstract discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.      Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Celgene, Janssen, AstraZeneca, Amgen, Takeda, Verastem, Celgene, Janssen, Karyopharm Therapeutics, Epizyme, Morphosys, Takeda, Pfizer  Research Funding (Inst): Janssen, Celgene/BMS  Travel, Accommodations, Expenses: Takeda  Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.